Concepedia

Owen A. O’Connor

OA

165

Publications

17.5K

Citations

61

H-Index

1989

Active since

Affiliations

Columbia University Irving Medical Center(Current)

Memorial Sloan Kettering Cancer Center

Columbia University

NYU Langone Health

The University of Texas MD Anderson Cancer Center

Owen A. O’Connor is an author at Columbia University Irving Medical Center specializing in medicine, pathology, and oncology.

ORCID

Top concepts

Publications per year

1989–2023

165

Publications

165

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

William Kevin Kelly, Owen A. O’Connor, Lee M. Krug et al. · Journal of Clinical Oncology · 2005 · 898 citations · Full text

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 840 citations · Full text

, , +11

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

Robert Z. Orlowski, Thomas E. Stinchcombe, Beverly S. Mitchell et al. · Journal of Clinical Oncology · 2002 · 760 citations

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Richard I. Fisher, Steven H. Bernstein, Brad S. Kahl et al. · Journal of Clinical Oncology · 2006 · 705 citations

Rows per page

1–5 of 165